背景:在过去十年中,有越来越多的有同情心的噬菌体治疗病例被报道,进行的临床试验数量有限,很少有不成功的临床试验报告。关于噬菌体在难治性感染中的作用只有很少的证据。我们的目标是在16例未解决的铜绿假单胞菌感染患者中提供最大的体恤使用单生物/噬菌体病例系列。
方法:我们总结了临床噬菌体微生物学易感性数据,给药方案,临床资料,以及用PASA16噬菌体治疗的所有病例的结果。在所有静脉注射噬菌体给药中,PASA16噬菌体是由适应性噬菌体疗法公司生产和无偿提供的。PASA16静脉给药,局部感染部位,或局部用于16名患者,有15名患者的数据,主要与骨关节和外来装置相关的感染。
结果:注意到一些轻微的副作用,包括肝功能酶升高和白细胞计数短暂减少。15例患者中有13例(86.6%)有良好的临床结果。报告了两个临床失败。最小治疗持续时间为8天,每天一次至两次。
结论:发现PASA16与抗生素在传统治疗方法以前失败的患者中相对成功。这样的1期前期队列可以概述潜在的临床方案,并促进未来试验的设计。
背景:该研究部分由以色列科学基金会IPMP(ISF_1349/20)资助,玫瑰信托(A2232),美国-以色列双边科学基金会(2017123),以及Milgrom家庭支持计划.
A growing number of compassionate phage therapy cases were reported in the last decade, with a limited number of clinical trials conducted and few unsuccessful clinical trials reported. There is only a little evidence on the role of phages in refractory infections. Our objective here was to present the largest compassionate-use single-organism/phage
case series in 16 patients with non-resolving Pseudomonas aeruginosa infections.
We summarized clinical phage microbiology susceptibility data, administration protocol, clinical data, and outcomes of all cases treated with PASA16 phage. In all intravenous phage administrations, PASA16 phage was manufactured and provided pro bono by Adaptive Phage Therapeutics. PASA16 was administered intravenously, locally to infection site, or by topical use to 16 patients, with data available for 15 patients, mainly with osteoarticular and foreign-device-associated infections.
A few minor side effects were noted, including elevated liver function enzymes and a transient reduction in white blood cell count. Good clinical outcome was documented in 13 out of 15 patients (86.6%). Two clinical failures were reported. The minimum therapy duration was 8 days with a once- to twice-daily regimen.
PASA16 with antibiotics was found to be relatively successful in patients for whom traditional treatment approaches have failed previously. Such pre-phase-1 cohorts can outline potential clinical protocols and facilitate the design of future trials.
The study was funded in part by The Israeli Science Foundation IPMP (ISF_1349/20), Rosetrees Trust (A2232), United States-Israel Binational Science Foundation (2017123), and the Milgrom Family Support Program.